Immunic posts investor presentation highlighting vidofludimus calcium Phase 3 MS program
IMUX•Phase 3 relapsing MS trials fully enrolled
Two Phase 3 relapsing MS trials, ENSURE-1 (N=1,121) and ENSURE-2 (N=1,100), are fully enrolled; top-line data expected by end of 2026. U.S. NDA submission targeted for mid-2027; potential U.S. regulatory approval projected in 2028.
Progressive MS program and funding outlook
Phase 2 CALLIPER in progressive MS showed numerical reductions in confirmed disability worsening with signals of disability improvement; Phase 3 program planned later in 2026. Funding expected into late 2027; U.S. intellectual property protection expected up to 2044.
Investor presentation outlines multiple sclerosis focus
Immunic outlined plans to pivot toward a fully integrated multiple sclerosis focus built around lead oral therapy vidofludimus calcium (IMU-838).
